Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
11 August 2016
GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option
11 August 2016
GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie
13 July 2016
GenSight Biologics announces successful IPO on Euronext Paris
05 July 2016
GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris
08 June 2016
GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
24 May 2016
GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext’s regulated market in Paris
29 February 2016
GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy
10 September 2015
GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010
23 July 2015
GenSight Biologics Closes $36 Million Series B Preferred Stock Financing
06 July 2015
GenSight Biologics Appoints Thomas Gidoin as Chief Financial Officer & Michael Wyzga to Board of Directors
View previous 9 articles
1
…
18
19
20
21
22
23
24
View next 9 articles
Go back to the page of the page